Page last updated: 2024-09-05

lapatinib and arry-334543

lapatinib has been researched along with arry-334543 in 3 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (arry-334543)	Trials (arry-334543)	Recent Studies (post-2010) (arry-334543)
1,919	305	1,442	12	0	11

Protein Interaction Comparison

Protein	Taxonomy	arry-334543 (IC50)
Epidermal growth factor receptor	Homo sapiens (human)	0.007
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	0.002
Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)	0.004

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, S; Chen, YZ; Ding, C; Hu, G; Jiang, Y; Li, L; Tan, C; Zhang, C; Zhang, W	1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP	1
Das, D; Hong, J	1

Reviews

1 review(s) available for lapatinib and arry-334543

Article	Year
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. European journal of medicinal chemistry, 2019, May-15, Volume: 170 Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines	2019

Other Studies

2 other study(ies) available for lapatinib and arry-334543

Article	Year
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy. Bioorganic & medicinal chemistry, 2017, 01-01, Volume: 25, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Green Fluorescent Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Docking Simulation; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Triazoles	2017
The target landscape of clinical kinase drugs. Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays	2017

Article

Year

Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.

Bioorganic & medicinal chemistry, 2017, 01-01, Volume: 25, Issue:1

Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Green Fluorescent Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Docking Simulation; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Triazoles

2017

The target landscape of clinical kinase drugs.

Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017